# Merus N.V.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/merus-n-v

- Industry: Biotechnology
- Headquarters: Utrecht, Netherlands
- Website: www.merus.nl
- Total disclosed funding: $155M
- Latest round: Series C (Aug 26, 2015)
- Investors on record: 10

## About

Founded in 2003 and based in the Netherlands, Merus N.V. operates as a biotechnology company that develops the Multiclonics platform used to screen and generate molecular and cell-based bispecific antibody therapeutics. The company has raised venture funding rounds from private equity investors, including Pfizer Venture Investments, Life Sciences Partners, and BVF Partners. In May 2016, the company was listed on the Nasdaq for an IPO (Initial Public Offering) under the ticker symbol MRUS. In August 2023, Merus N.V. raised USD 150 million in a Private Placement, selling 6.82 million shares at USD 22 on the Nasdaq Global Market. The firm as of January 2024, is led by its President and CEO, Bill Lundberg.

The company's R&D team offers IgG antibody therapeutics through the Multiclonics platform that discovers and screens bi-specific and tri-specific antibodies capable of binding two or more targets for the treatment of patients with cancer, as well as infectious and inflammatory diseases. Merus is also working on clinical trials for drug candidates, namely MCLA-128, MCLA-129, MCLA-158, MCLA-145, and ONO-4685.

Merus N.V. generates revenue by collaborating with pharmaceutical and biotechnology companies and academic institutions to extend its platform and product candidates' reach and capabilities.

## Funding rounds

- Series C, Aug 26, 2015, $82M — Sofinnova Investments, Novartis Venture Fund, EQT Life Sciences, Johnson & Johnson Innovation, Bay City Capital, Tekla Capital Management, Pfizer Venture Investments, Novo Holdings, Rock Springs Capital
- Series B, Oct 3, 2013, $42M — Novartis Venture Fund, EQT Life Sciences, Johnson & Johnson Innovation, Bay City Capital, Pfizer Venture Investments
- Series B, Jun 1, 2009, $30M — Novartis Venture Fund, EQT Life Sciences, Bay City Capital, Aglaia Oncology Funds, Pfizer Venture Investments
- Series A, Jan 17, 2006 — Aglaia Oncology Funds

## Investors

- Aglaia Oncology Funds (https://capitalatlas.ai/funds/aglaia-oncology-funds) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- Novo Holdings — Series C
- Rock Springs Capital — Series C